Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 692
Filter
1.
Port J Card Thorac Vasc Surg ; 31(1): 59-62, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38743514

ABSTRACT

INTRODUCTION: Purulent pericarditis secondary to esophago-pericardial fistula is a serious complication that has been previously reported in patients with esophageal cancer treated with radio/chemotherapy and esophageal stenting. However, the presence of esophago-pericardial fistula as the first manifestation of advanced carcinoma of the esophagus is exceedingly infrequent. We report the case of a 61-year-old male who presented with sepsis, cardiac tamponade and septic shock who was found to have an esophago-pericardial fistula secondary to squamous carcinoma of the esophagus. Emergency pericardiocentesis was performed with subsequent hemodynamic improvement. The drained pericardial fluid was purulent in nature and cultures were positive for Streptococcus anginosus. A CT scan followed by upper gastrointestinal endoscopy with tissue biopsy confirmed the diagnosis of squamous cell carcinoma of the esophagus. A self-expanding covered stent was endoscopically placed to exclude the fistula and restore the esophageal lumen. In this report, we discuss some aspects related to the diagnosis and management of this serious clinical entity.


Subject(s)
Carcinoma, Squamous Cell , Esophageal Fistula , Esophageal Neoplasms , Pericarditis , Humans , Male , Middle Aged , Esophageal Neoplasms/pathology , Esophageal Neoplasms/complications , Pericarditis/microbiology , Pericarditis/etiology , Pericarditis/therapy , Pericarditis/diagnosis , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/diagnosis , Esophageal Fistula/etiology , Esophageal Fistula/diagnosis , Streptococcal Infections/complications , Streptococcal Infections/diagnosis , Streptococcus anginosus/isolation & purification , Pericardiocentesis , Stents , Tomography, X-Ray Computed , Cardiac Tamponade/etiology
2.
Mayo Clin Proc ; 99(5): 795-811, 2024 May.
Article in English | MEDLINE | ID: mdl-38702128

ABSTRACT

Inflammatory disease of the pericardium represents a relatively common presentation, especially among the young. For the most part, inflammatory pericardial disease can be expeditiously and effectively managed without significant sequelae. However, some individuals present with severe and recurrent illness, representing significant therapeutic challenges. During the past decade, there have been great strides made in developing an evidence-based approach to management of inflammatory pericardial disease, the result of which has been the development of (1) a systematic, protocoled approach to initial care; (2) targeted therapeutics; and (3) specialized, collaborative, and integrated care pathways. Herein we present a review of the current state of the art as it pertains to the diagnostic evaluation and therapeutic considerations in inflammatory pericardial disease with a focus on acute and complicated pericarditis.


Subject(s)
Pericarditis , Humans , Pericarditis/diagnosis , Pericarditis/therapy , Pericarditis/etiology , Acute Disease
3.
Catheter Cardiovasc Interv ; 103(6): 1062-1068, 2024 May.
Article in English | MEDLINE | ID: mdl-38651541

ABSTRACT

A 55-year-old male with acute pericarditis presented with low-pressure cardiac tamponade (LPCT) unresponsive to volume infusion. Subsequent pericardiocentesis resulted in hemodynamic improvement and unmasking of pericardial constriction. This case provides illustrative hemodynamic tracings of LPCT. Additionally, the presence of concurrent pericardial constriction that may indicate a plausible underlying mechanism for the blunted responsiveness to fluid expansion in LPCT. The underlying physiologic processes and the associated hemodynamic tracings are discussed.


Subject(s)
Cardiac Tamponade , Hemodynamics , Pericardiocentesis , Humans , Cardiac Tamponade/physiopathology , Cardiac Tamponade/etiology , Cardiac Tamponade/diagnostic imaging , Cardiac Tamponade/surgery , Male , Middle Aged , Treatment Outcome , Pericarditis/physiopathology , Pericarditis/therapy , Pericarditis/diagnostic imaging , Pericarditis/etiology , Pericarditis/diagnosis , Acute Disease
4.
Prim Care ; 51(1): 111-124, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38278565

ABSTRACT

Pericarditis typically presents with classic symptoms of acute sharp, retrosternal, and pleuritic chest pain. It can have several different underlying causes including viral, bacterial, and autoimmune etiologies. The mainstays of pericarditis treatment are nonsteroidal anti-inflammatory drugs and colchicine with glucocorticoids or other immunosuppressive drugs used for refractory cases and relapse. Myocarditis is an inflammatory disease of the cardiac muscle that is caused by a variety of infectious and noninfectious conditions. It mainly affects young adults (median age 30-45 years), and men more than women. The clinical manifestations of myocarditis are highly variable, so a high level of suspicion in the early stage of disease is important to facilitate diagnosis. The treatment of myocarditis includes nonspecific treatment aimed at complications such as heart failure and arrhythmia, as well as specific treatment aimed at underlying causes. Pericarditis and myocarditis associated with vaccine have been extremely rare before coronavirus disease 2019 (COVID-19). There is a small increase of incidence after COVID-19 messenger ribonucleic acid vaccine, but the relative risk for pericarditis and myocarditis due to severe acute respiratory syndrome coronavirus 2 infection is much higher. Therefore, vaccination against COVID-19 is currently recommended for everyone aged 6 years and older.


Subject(s)
COVID-19 , Myocarditis , Pericarditis , Male , Young Adult , Humans , Female , Adult , Middle Aged , Myocarditis/diagnosis , Myocarditis/therapy , Affect , COVID-19 Vaccines , Pericarditis/diagnosis , Pericarditis/therapy , Vaccination
6.
Curr Probl Cardiol ; 49(1 Pt C): 102116, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37802168

ABSTRACT

Mpox, a novel epidemic disease, has broken out the period of coronavirus disease 2019 since May 2022, which was caused by the mpox virus. Up to 12 September 2023, there are more than 90,439 confirmed mpox cases in over 115 countries all over the world. Moreover, the outbreak of mpox in 2022 was verified to be Clade II rather than Clade I. Highlighting the significance of this finding, a growing body of literature suggests that mpox may lead to a series of cardiovascular complications, including myocarditis and pericarditis. It is indeed crucial to acquire more knowledge about mpox from a perspective from the clinical cardiologist. In this review, we would discuss the epidemiological characteristics and primary treatments of mpox to attempt to provide a framework for cardiovascular physicians.


Subject(s)
COVID-19 , Cardiovascular Diseases , Mpox (monkeypox) , Myocarditis , Pericarditis , Humans , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , COVID-19/epidemiology , Pericarditis/epidemiology , Pericarditis/etiology , Pericarditis/therapy
7.
Ter Arkh ; 95(11): 965-969, 2023 Dec 22.
Article in Russian | MEDLINE | ID: mdl-38158953

ABSTRACT

A description of a COVID-19 patient with the development of exudative pericarditis complicated by cardiac tamponade is provid. A peculiarity of this case is the presence of an underlying disease in the patient (chronic lymphocytic leukemia), which was in remission for 1.5 years after chemotherapy. Another feature of the patient was the relatively small area of lung damage and the hemorrhagic nature of the pericardial effusion, which persisted for a long time. The insignificant activity of inflammatory markers was noteworthy. Possible mechanisms of development and features of the course of exudative pericarditis in the described patient, issues of diagnosis and treatment of this category of patients are discusse.


Subject(s)
COVID-19 , Cardiac Tamponade , Pericardial Effusion , Pericarditis , Humans , COVID-19/complications , COVID-19/diagnosis , Pericarditis/diagnosis , Pericarditis/etiology , Pericarditis/therapy , Pericardial Effusion/diagnosis , Pericardial Effusion/etiology , Pericardial Effusion/therapy , Cardiac Tamponade/diagnosis , Cardiac Tamponade/etiology , Cardiac Tamponade/therapy
8.
Future Cardiol ; 19(4): 197-202, 2023 Mar.
Article in English | MEDLINE | ID: mdl-37313836

ABSTRACT

We present a case of a 54-year-old gentleman with a history of hypertension and chronic HIV who presented with fever and epigastric pain, found to have elevated troponin-I levels and diffuse ST-segement elevations on ECG without clinical evidence of ischemia concerning for myopericarditis. Initial laboratory findings also included thrombocytopenia and elevated aminotransferases as well as computed tomography imaging revealing splenic infarcts. Given plausible exposure to ticks, this led to the eventual diagnosis of anaplasmosis confirmed on PCR assay. Cardiac MRI images confirmed myocardial involvement, which resolved with antibiotic treatment. While rare, cardiac involvement is possible sequelae of anaplasmosis infection as illustrated by this case.


Subject(s)
Anaplasmosis , Myocarditis , Pericarditis , Male , Animals , Humans , Middle Aged , Anaplasmosis/complications , Anaplasmosis/diagnosis , Pericarditis/diagnosis , Pericarditis/etiology , Pericarditis/therapy , Myocarditis/diagnosis , Myocarditis/etiology , Myocarditis/therapy , Troponin I
9.
Emerg Med Pract ; 25(7): 1-24, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37352407

ABSTRACT

Pericarditis and myocarditis represent a challenging set of diseases to diagnose and treat. These diseases typically present with chest pain and dyspnea in previously healthy young people, often in the weeks following a viral illness, including COVID-19. Nonetheless, the etiologies can be very diverse, including infectious, noninfectious, drug-induced, and autoimmune causes. This review focuses on the evaluation, diagnosis, and management of emergency department patients presenting with pericarditis and myocarditis and summarizes current guidelines and best-practice medical management strategies in order to avoid potential life-threatening cardiac complications.


Subject(s)
COVID-19 , Myocarditis , Pericarditis , Humans , Adolescent , Myocarditis/diagnosis , Myocarditis/therapy , Myocarditis/etiology , COVID-19/therapy , Pericarditis/diagnosis , Pericarditis/therapy , Pericarditis/etiology , Emergency Service, Hospital , Diagnosis, Differential , COVID-19 Testing
10.
Can J Cardiol ; 39(8): 1059-1066, 2023 08.
Article in English | MEDLINE | ID: mdl-37201721

ABSTRACT

Pericardial disease in the developing world is dominated primarily by effusive and constrictive syndromes and contributes to the acute and chronic heart failure burden in many regions. The confluence of geography (location in the tropics), a significant burden of diseases of poverty and neglect, and a significant contribution of communicable diseases to the general burden of disease is reflected in the wide etiological spectrum of causes of pericardial disease. The prevalence of Mycobacterium tuberculosis in particular, is high throughout much of the developing world where it is the most frequent and important cause of pericarditis and is associated with significant morbidity and mortality. Acute viral/idiopathic pericarditis, which is the primary manifestation of pericardial disease in the developed world is believed to occur significantly less frequently in the developing world. Although diagnostic approaches and criteria to establish the diagnosis of pericardial disease are similar throughout the globe, resource constraints such as access to multimodality imaging and hemodynamic assessment are a major limitation in much of the developing world. These important considerations significantly influence the diagnostic and treatment approaches, and outcomes related to pericardial disease.


Subject(s)
Heart Failure , Myocarditis , Pericardial Effusion , Pericarditis, Constrictive , Pericarditis , Humans , Pericarditis, Constrictive/diagnosis , Pericardial Effusion/diagnosis , Pericarditis/diagnosis , Pericarditis/epidemiology , Pericarditis/therapy , Pericardium , Heart Failure/diagnosis , Heart Failure/epidemiology , Heart Failure/etiology , Myocarditis/complications
11.
Herz ; 48(3): 195-205, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37195428

ABSTRACT

The causes of cardiac inflammation during the COVID-19 pandemic are manifold and complex, and may have changed with different virus variants and vaccinations. The underlying viral etiology is self-evident, but its role in the pathogenic process is diverse. The view of many pathologists that myocyte necrosis and cellular infiltrates are indispensable for myocarditis does not suffice and contradicts the clinical criteria of myocarditis, i.e., a combination of serological evidence of necrosis based on troponins or MRI features of necrosis, edema, and inflammation based on prolonged T1 and T2 times and late gadolinium enhancement. The definition of myocarditis is still debated by pathologists and clinicians. We have learned that myocarditis and pericarditis can be induced by the virus via different pathways of action such as direct viral damage to the myocardium through the ACE2 receptor. Indirect damage occurs via immunological effector organs such as the innate immune system by macrophages and cytokines, and then later the acquired immune system via T cells, overactive proinflammatory cytokines, and cardiac autoantibodies. Cardiovascular diseases lead to more severe courses of SARS-CoV­2 disease. Thus, heart failure patients have a double risk for complicated courses and lethal outcome. So do patients with diabetes, hypertension, and renal insufficiency. Independent of the definition, myocarditis patients benefitted from intensive hospital care, ventilation, if needed, and cortisone treatment. Postvaccination myocarditis and pericarditis affect primarily young male patients after the second RNA vaccine. Both are rare events but severe enough to deserve our full attention, because treatment according to current guidelines is available and necessary.


Subject(s)
COVID-19 , Myocarditis , Pericarditis , Humans , Male , SARS-CoV-2 , Autoimmunity , Pandemics , Contrast Media , Gadolinium/therapeutic use , Inflammation , Pericarditis/therapy , Arrhythmias, Cardiac , Cytokines , Vaccination
12.
BMC Cardiovasc Disord ; 23(1): 259, 2023 05 19.
Article in English | MEDLINE | ID: mdl-37208627

ABSTRACT

BACKGROUND: Post cardiac injury syndrome (PCIS) is characterized by the development of pericarditis with or without pericardial effusion due to a recent cardiac injury. The relatively low incidence makes diagnosis of PCIS after implantation of a pacemaker easily be overlooked or underestimated. This report describes one typical case of PCIS. CASE PRESENTATION: We present a case report of a 94-year-old male with a history of sick sinus syndrome managed with a dual-chamber pacemaker who presented with PCIS after two months of pacemaker implantation. He gradually developed chest discomfort, weakness, tachycardia and paroxysmal nocturnal dyspnea and cardiac tamponade after two months of pacemaker. Post-cardiac injury syndrome related to dual-chamber pacemaker implantation was considered based on exclusion of other possible causes of pericarditis. His therapy was drainage of pericardial fluid and managed with a combination of colchicine and support therapy. He was placed on long-term colchicine therapy to prevent any recurrences. CONCLUSION: This case illustrated that PCIS can occur after minor myocardial injury, and that the possibility of PCIS should be considered if there is a history of possible cardiac insult.


Subject(s)
Cardiac Tamponade , Heart Injuries , Pacemaker, Artificial , Pericardial Effusion , Pericarditis , Male , Humans , Aged, 80 and over , Pacemaker, Artificial/adverse effects , Pericarditis/diagnosis , Pericarditis/etiology , Pericarditis/therapy , Heart Injuries/diagnostic imaging , Heart Injuries/etiology , Heart Injuries/therapy , Pericardial Effusion/diagnostic imaging , Pericardial Effusion/etiology , Cardiac Tamponade/diagnostic imaging , Cardiac Tamponade/etiology , Cardiac Tamponade/therapy
13.
Can J Cardiol ; 39(8): 1067-1077, 2023 08.
Article in English | MEDLINE | ID: mdl-37086835

ABSTRACT

Pericardial effusion is the most common manifestation of pericardial diseases during pregnancy. This effusion is benign, mild, or moderate, well tolerated, with spontaneous resolution after delivery; no specific treatment is required. Acute pericarditis is the second most common condition, usually requiring medical therapy during pregnancy. Cardiac tamponade and constrictive pericarditis are rare in pregnancy. Pre-pregnancy counselling is essential in women of childbearing age with recurrent pericarditis to plan pregnancy in a phase of disease quiescence and to review therapy. High-dose aspirin or nonselective nonsteroidal anti-inflammatory drugs, such as ibuprofen and indomethacin, can be used up to the 20th week of gestation. Low-dose prednisone (2.5-10 mg/d) can be administered throughout pregnancy. All of these medications, apart from high-dose aspirin, may be used during lactation. Colchicine is compatible with pregnancy and breastfeeding, and it can be continued throughout pregnancy to prevent recurrences. Appropriate follow-up with a multidisciplinary team with experience in the field is recommended throughout pregnancy to ensure good maternal and fetal outcomes.


Subject(s)
Cardiac Tamponade , Pericardial Effusion , Pericarditis, Constrictive , Pericarditis , Pregnancy , Humans , Female , Pericarditis/therapy , Pericarditis/drug therapy , Aspirin/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
14.
J Cardiol ; 82(4): 268-273, 2023 10.
Article in English | MEDLINE | ID: mdl-36906259

ABSTRACT

BACKGROUND: Acute pericarditis occasionally requires invasive treatment, and may recur after discharge. However, there are no studies on acute pericarditis in Japan, and its clinical characteristics and prognosis are unknown. METHODS: This was a single-center, retrospective cohort study of clinical characteristics, invasive procedures, mortality, and recurrence in patients with acute pericarditis hospitalized from 2010 to 2022. The primary in-hospital outcome was adverse events (AEs), a composite of all-cause mortality and cardiac tamponade. The primary outcome in the long-term analysis was hospitalization for recurrent pericarditis. RESULTS: The median age of all 65 patients was 65.0 years [interquartile range (IQR), 48.0-76.0 years], and 49 (75.3 %) were male. The etiology of acute pericarditis was idiopathic in 55 patients (84.6 %), collagenous in 5 (7.6 %), bacterial in 1 (1.5 %), malignant in 3 (4.6 %), and related to previous open-heart surgery in 1 (1.5 %). Of the 8 patients (12.3 %) with in-hospital AE, 1 (1.5 %) died during hospitalization and 7 (10.8 %) developed cardiac tamponade. Patients with AE were less likely to have chest pain (p = 0.011) but were more likely to have symptoms lasting 72 h after treatment (p = 0.006), heart failure (p < 0.001), and higher levels of C-reactive protein (p = 0.040) and B-type natriuretic peptide (p = 0.032). All patients complicated with cardiac tamponade were treated with pericardial drainage or pericardiotomy. We analyzed 57 patients for recurrent pericarditis after excluding 8 patients: 1 with in-hospital death, 3 with malignant pericarditis, 1 with bacterial pericarditis, and 3 lost to follow-up. During a median follow-up of 2.5 years (IQR 1.3-3.0 years), 6 patients (10.5 %) had recurrences requiring hospitalization. The recurrence rate of pericarditis was not associated with colchicine treatment or aspirin dose or titration. CONCLUSIONS: In acute pericarditis requiring hospitalization, in-hospital AE and recurrence were each observed in >10 % of patients. Further large studies on treatment are warranted.


Subject(s)
Hospitalization , Pericarditis , Aged , Female , Humans , Male , Middle Aged , Acute Disease , Cardiac Tamponade/epidemiology , Cardiac Tamponade/therapy , Hospital Mortality , Japan/epidemiology , Pericarditis/mortality , Pericarditis/therapy , Recurrence , Retrospective Studies
15.
Curr Cardiol Rep ; 25(3): 157-170, 2023 03.
Article in English | MEDLINE | ID: mdl-36749541

ABSTRACT

PURPOSE OF REVIEW: While there have now been a variety of large reviews on adult pericarditis, this detailed review specifically focuses on the epidemiology, clinical presentation, diagnosis, and management of pediatric pericarditis. We have tried to highlight most pediatric studies conducted on this topic, with special inclusion of important adult studies that have shaped our understanding of and management for acute and recurrent pericarditis. RECENT FINDINGS: We find that the etiology of pediatric pericarditis differs from adult patients with pericarditis and has evolved over the years. Also, with the current COVID-19 pandemic, it is important for pediatric clinicians to be aware of pericardial involvement both due to the infection and from vaccination. Oftentimes, pericarditis maybe the only cardiac involvement in children with COVID-19, and so caregivers should maintain a high index of suspicion when they encounter children with pericarditis.  Large-scale contemporary epidemiological data regarding incidence and prevalence of both acute and recurrent pericarditis is lacking in pediatrics, and future studies should focus on highlighting this important research gap. Most of the current management strategies for pediatric pericarditis are from experiences gathered from adult data. Pediatric multicenter trials are warranted to understand the best management strategy for those with acute and recurrent pericarditis. CASE VIGNETTE: A 6-year-old child with a past history of pericarditis almost 2 months ago comes in with a 2-day history of chest pain and fever. Per mother, he stopped his steroids about 2 weeks ago, and for the last 2 days has had a temperature of 102F and has been complaining of sharp mid-sternal chest pain that gets worse when he lies down and is relieved when he sits up and leans forward. On examination, he is tachycardic (heart rate 160 bpm), with normal blood pressure for age. He appears to be in pain (5/10), and on auscultation has a pericardial friction rub. His lab studies are notable for elevated white blood cell count and inflammatory markers (CRP and ESR). His electrocardiogram reveals sinus tachycardia and diffuse ST-elevation in all precordial leads. His echocardiogram demonstrates normal biventricular function and a trace pericardial effusion. His cardiac MRI confirms recurrent pericarditis. He is started on indomethacin and colchicine. He has complete resolution of his symptoms by day 3 of admission and is discharged with close follow-up.


Subject(s)
COVID-19 , Pericardial Effusion , Pericarditis , Child , Humans , Male , Chest Pain/complications , COVID-19/epidemiology , COVID-19/complications , Pandemics , Pericardial Effusion/etiology , Pericarditis/diagnosis , Pericarditis/epidemiology , Pericarditis/therapy
16.
Can J Cardiol ; 39(8): 1111-1120, 2023 08.
Article in English | MEDLINE | ID: mdl-36740019

ABSTRACT

Pericardial syndromes encompass different clinical conditions from acute pericarditis to idiopathic chronic pericardial effusion. Transthoracic echocardiography is the first and most important initial diagnostic imaging modality in most patients affected by pericardial disease. However, cardiac computed tomography (CCT) and cardiac magnetic resonance imaging (CMR) have recently gained a pivotal role in cardiology, and recent reports have supported the role of both of these advanced techniques in the evaluation and guiding therapy of pericardial disease. Most promising is the capability of CMR to identify the presence of pericardial inflammation, carrying both diagnostic and prognostic value in the setting of recurrent and chronic pericarditis. In addition, CCT permits accurate evaluation of the presence and extension of pericardial calcification, providing important information in confirming the diagnosis of constrictive pericarditis and during the preprocedural planning for patients undergoing pericardiectomy. Both CCT and CMR require specific expertise, especially for the evaluation of pericardial disease. The aim of the present review is to provide physicians an updated overview of CCT and CMR in pericardial disease, focusing on technical issues, recent research findings, and potential clinical applications.


Subject(s)
Pericardial Effusion , Pericarditis, Constrictive , Pericarditis , Humans , Pericarditis/diagnostic imaging , Pericarditis/therapy , Pericardium/diagnostic imaging , Pericardium/pathology , Magnetic Resonance Imaging , Pericarditis, Constrictive/diagnostic imaging , Pericarditis, Constrictive/surgery , Pericardial Effusion/diagnostic imaging , Pericardial Effusion/therapy
17.
Prehosp Emerg Care ; 27(3): 379-383, 2023.
Article in English | MEDLINE | ID: mdl-36629493

ABSTRACT

This case presentation describes the clinical management and course of an adult patient found to be in cardiac tamponade secondary to purulent pericarditis. This etiology represents an uncommon cause of pericardial tamponade and highlights the importance of recognizing clinical signs of this physiological state despite the uncommon presentation. This also reinforces that critical care transport teams must be trained and facile with high acuity-low occurrence skills such as pericardiocentesis as such time-sensitive measures may be necessary to stabilize patients for transport. The patient in this case had clinical improvement after pericardiocentesis was performed and this allowed for the safe transport of the patient to a tertiary care center.


Subject(s)
Cardiac Tamponade , Emergency Medical Services , Pericarditis , Adult , Humans , Cardiac Tamponade/therapy , Cardiac Tamponade/complications , Pericardiocentesis/adverse effects , Pericarditis/therapy , Pericarditis/complications
18.
Int J Rheum Dis ; 26(2): 337-343, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36537284

ABSTRACT

AIMS: To identify peripheral blood cellular correlates of active pericarditis and to verify whether peripheral blood neutrophils, lymphocytes and the neutrophil to-lymphocyte ratio (NLR) are associated with disease phenotype or prognosis. METHODS: Observational prospective study on a cohort of 63 patients with idiopathic pericarditis followed for 12 months after each pericarditis recurrence. Two distinct analyses were performed: the "index attack" analysis focused on the first pericarditis episode in each patient, while the "all attacks" analysis included all episodes occurring during the study. RESULTS: Absolute and relative neutrophilia and lymphopenia, together with high NLR, were observed during active pericarditis, as compared with disease remission, at both analyses. Neutrophils showed a positive correlation with plasma C-reactive protein levels, while lymphocyte count showed a negative correlation. Relative neutrophil count was higher, and lymphocyte count lower in patients with pleural effusion; a higher NLR and lower absolute lymphocyte count were observed in those with peritoneal involvement. No correlations were found between peripheral blood neutrophil or lymphocyte counts and size of pericardial effusion, or with the presence of myocardial involvement. Peripheral neutrophilia, lymphopenia and NLR during acute attacks predicted the number of recurrences in the following 12 months. CONCLUSIONS: Peripheral blood neutrophilia and lymphopenia are typical of acute idiopathic pericarditis. Acute attacks of pericarditis are associated with neutrophilia and lymphopenia, as compared with disease remission. During acute attacks, neutrophilia and lymphopenia reflect the extent of serosal inflammation and could help to customize therapeutic management after remission has been achieved.


Subject(s)
Bone Marrow Diseases , Lymphopenia , Pericarditis , Humans , Neutrophils , Prospective Studies , Lymphopenia/diagnosis , Lymphocytes , Lymphocyte Count , Prognosis , Inflammation , Pericarditis/diagnosis , Pericarditis/therapy , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...